oncology image min - Oncology


FDA PK/PD Phase I & II oncology reviews


Phase I & II oncology studies designed

Cancer experts. Answer experts.

D2V Clinical knows oncology development. Our team of seasoned experts have been instrumental in the successful launch of numerous contemporary precision medicines. Their expertise spans a wide range, from targeted therapies and immunotherapies to advanced cell and gene therapies, driving innovation in the field of oncology.

We bring together scientific expertise, regulatory acumen, and operational excellence to provide comprehensive assistance throughout the early-phase drug development process. D2V Clinical is dedicated to helping our sponsors accelerate market approvals for oncology compounds.



  • Anal
  • Basal, squamous cell carcinoma
  • Bladder
  • Brain metastases
  • Breast carcinoid tumors
  • Cholangiocarcinoma
  • Colorectal Esophageal
  • Gall bladder
  • Gastric
  • GI stromal tumor
  • Glioblastoma multiforme
  • Head & neck
  • Hepatocellular
  • Lung (NSCLC, SCLC)
  • Melanoma
  • Neuroectodermal tumors
  • Neuroendocrine
  • Ovarian
  • Pancreatic
  • Prostate
  • Renal cell
  • Salivary gland
  • Thyroid
We are here to help

Unlock the potential of your oncology asset with D2V Clinical

Partnering with D2V Clinical means gaining access to a wealth of experience and tailored solutions specifically designed for early-phase oncology research. Our team of experts collaborates closely with clients to develop comprehensive trial strategies, optimize study design, and overcome potential challenges.

We provide expert guidance in selecting the right patient populations, identifying key biomarkers, and leveraging innovative technologies to maximize trial success. Our agile approach ensures efficient patient enrollment, robust data collection, and insightful analysis, delivering the critical insights needed to advance oncology therapies rapidly.